147 related articles for article (PubMed ID: 8858517)
1. Comparison of bromodeoxyuridine uptake and MIB 1 immunoreactivity in medulloblastomas determined with single and double immunohistochemical staining methods.
Onda K; Davis RL; Edwards MS
J Neurooncol; 1996 Aug; 29(2):129-36. PubMed ID: 8858517
[TBL] [Abstract][Full Text] [Related]
2. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
[TBL] [Abstract][Full Text] [Related]
3. Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme.
Onda K; Davis RL; Wilson CB; Hoshino T
Acta Neuropathol; 1994; 87(6):586-93. PubMed ID: 8091951
[TBL] [Abstract][Full Text] [Related]
4. Cell kinetics of medulloblastomas.
Ito S; Hoshino T; Prados MD; Edwards MS
Cancer; 1992 Aug; 70(3):671-8. PubMed ID: 1623482
[TBL] [Abstract][Full Text] [Related]
5. Medulloblastoma: evaluation of proliferative index by monoclonal antibody Mib-1, its prognostic correlation and therapeutic implications.
Ferrari AF; Araújo MB; Aguiar PH; Plese JP
Arq Neuropsiquiatr; 2003 Sep; 61(3A):547-51. PubMed ID: 14513155
[TBL] [Abstract][Full Text] [Related]
6. In vivo bromodeoxyuridine incorporation in human gastric cancer: a study on formalin-fixed and paraffin-embedded sections.
Danova M; Riccardi A; Brugnatelli S; Fiocca R; Girino M; Villani L; Giordano P; Dionigi P; Giordano M; Buttini R
Histochem J; 1988 Mar; 20(3):125-30. PubMed ID: 2842278
[TBL] [Abstract][Full Text] [Related]
7. Proliferative activity of central neurocytoma: measurement of tumor volume doubling time, MIB-1 staining index and bromodeoxyuridine labeling index.
Fujimaki T; Matsuno A; Sasaki T; Toyoda T; Matsuura R; Ogai M; Kitanaka C; Asai A; Matsutani M; Kirino T
J Neurooncol; 1997 Apr; 32(2):103-9. PubMed ID: 9120539
[TBL] [Abstract][Full Text] [Related]
8. Effects of fixation time and enzymatic digestion on immunohistochemical demonstration of bromodeoxyuridine in formalin-fixed, paraffin-embedded tissue.
Hayashi Y; Koike M; Matsutani M; Hoshino T
J Histochem Cytochem; 1988 May; 36(5):511-4. PubMed ID: 3282006
[TBL] [Abstract][Full Text] [Related]
9. [A review of cell kinetic studies on brain tumors with special reference to anti-bromodeoxyuridine monoclonal antibody method].
Nagashima T; Hoshino T
No Shinkei Geka; 1984 Aug; 12(9):1007-18. PubMed ID: 6390240
[TBL] [Abstract][Full Text] [Related]
10. Are childhood and adult medulloblastomas different? A comparative study of clinicopathological features, proliferation index and apoptotic index.
Sarkar C; Pramanik P; Karak AK; Mukhopadhyay P; Sharma MC; Singh VP; Mehta VS
J Neurooncol; 2002 Aug; 59(1):49-61. PubMed ID: 12222838
[TBL] [Abstract][Full Text] [Related]
11. Flow-cytometric DNA analysis and immunohistochemical measurement of Ki-67 and BUdR labeling indices in human brain tumors.
Nishizaki T; Orita T; Furutani Y; Ikeyama Y; Aoki H; Sasaki K
J Neurosurg; 1989 Mar; 70(3):379-84. PubMed ID: 2536805
[TBL] [Abstract][Full Text] [Related]
12. A cytomorphological scheme of differentiating neuronal phenotypes in cerebellar medulloblastomas based on immunolocalization of class III beta-tubulin isotype (beta III) and proliferating cell nuclear antigen (PCNA)/cyclin.
Katsetos CD; Krishna L; Frankfurter A; Karkavelas G; Wolfe DE; Valsamis MP; Schiffer D; Vlachos IN; Urich H
Clin Neuropathol; 1995; 14(2):72-81. PubMed ID: 7606900
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
[TBL] [Abstract][Full Text] [Related]
14. Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas.
Langford LA; Cooksley CS; DeMonte F
Hum Pathol; 1996 Apr; 27(4):350-4. PubMed ID: 8617477
[TBL] [Abstract][Full Text] [Related]
15. In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling.
Hoshino T; Nagashima T; Murovic JA; Wilson CB; Edwards MS; Gutin PH; Davis RL; DeArmond SJ
J Neurosurg; 1986 Mar; 64(3):453-9. PubMed ID: 3950723
[TBL] [Abstract][Full Text] [Related]
16. Proliferating cell nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumours in paraffin embedded sections.
Sasaki A; Naganuma H; Kimura R; Isoe S; Nakano S; Nukui H; Suzuki K; Kawaoi A
Acta Neurochir (Wien); 1992; 117(3-4):178-81. PubMed ID: 1357920
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 (MIB 5) immunostaining of mouse lung tumors induced by 4-nitroquinoline 1-oxide.
Ito T; Mitui H; Udaka N; Hayashi H; Okudela K; Kanisawa M; Kitamura H
Histochem Cell Biol; 1998 Dec; 110(6):589-93. PubMed ID: 9860257
[TBL] [Abstract][Full Text] [Related]
18. Correlation of in vitro bromodeoxyuridine labeling index and DNA aneuploidy with survival or recurrence in brain-tumor patients.
Nishizaki T; Orita T; Kajiwara K; Ikeda N; Ohshita N; Nakayama H; Furutani Y; Ikeyama Y; Akimura T; Kamiryo T
J Neurosurg; 1990 Sep; 73(3):396-400. PubMed ID: 1696625
[TBL] [Abstract][Full Text] [Related]
19. Pale islands in medulloblastoma consist of differentiated cells with low growth potential.
Iijima M; Nakazato Y
Pathol Int; 1997 Jan; 47(1):25-30. PubMed ID: 9051689
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical assessment of the MIB-1 Labeling Index in human hepatoblastoma and its prognostic relevance.
Ara T; Fukuzawa M; Oue T; Komoto Y; Kusafuka T; Imura K; Okada A
J Pediatr Surg; 1997 Dec; 32(12):1690-4. PubMed ID: 9434000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
